Seer, Inc. develops and commercializes research-use proteomics products centered on its Proteograph Product Suite. The suite integrates proprietary engineered nanoparticles, optimized consumables, automation instrumentation and analytical software for proteomic analysis in research laboratories, academic institutions and biopharmaceutical settings.
SEER news commonly covers financial results and outlook, Proteograph adoption, research collaborations in multi-omic and population-scale studies, intellectual-property developments involving particle-based protein enrichment, and commercial leadership changes. Company updates also include governance and shareholder matters, including board responses to unsolicited proposals, director nominations, rights plans and other capital-structure actions.
Seer (SEER) will showcase early PRECISE-SG100K proteomics findings at the HUPO 2026 World Congress in Singapore.
Researchers from Nanyang Technological University will present initial data from the 10,000-participant PRECISE-SG100K study, which integrates deep, unbiased mass spectrometry-based proteomics with genomic, clinical and phenotypic data from Singapore's multi-ethnic population. The study uses Seer's Proteograph® Product Suite with high-performance LC-MS, which can increase plasma protein coverage by approximately 7 to 10-fold versus direct plasma analysis, enabling detection of lower-abundance proteins and potential biomarkers. Seer will also host a breakfast symposium and present a poster on quantitative fidelity requirements in large-scale proteomics.
Seer (SEER) announced a leadership change as President, Chief Financial Officer and Treasurer David Horn will depart the company effective October 1, 2026 to join a private company.
On the same date, Vice President of Financial Planning & Analysis Charles Endweiss will become Treasurer, principal financial officer and principal accounting officer. Seer’s CEO highlighted Horn’s six-year tenure and described Endweiss as a long-time finance leader with deep knowledge of the business.
Summary not available.
Summary not available.
Seer (Nasdaq: SEER) reported second quarter 2026 revenue of $3.1 million, down 23% from $4.1 million a year earlier, mainly from lower product and service revenue amid macro headwinds and elongated sales cycles. Gross profit was $1.5 million with a 49% gross margin.
Operating expenses fell 19% to $18.3 million, driven largely by lower employee and stock-based compensation, reducing net loss to $16.9 million from $19.4 million. The company ended June 30, 2026 with about $209.5 million in cash, cash equivalents and investments and had repurchased roughly 200,000 Class A shares. Seer reaffirmed its full-year 2026 revenue outlook of $16–$18 million, implying about 3% growth at the midpoint over 2025.
Seer (Nasdaq: SEER) announced it will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, MA. Seer’s management is scheduled to present on Wednesday, August 12 from 8:00 a.m. to 8:25 a.m. Eastern Time. A live webcast and archived replay will be available on the Investor section of the company’s website.
Seer (Nasdaq: SEER) announced it will report its second quarter 2026 financial results on Tuesday, August 11, 2026. Company management will host a webcasted conference call starting at 1:30 p.m. Pacific / 4:30 p.m. Eastern, with live audio and replay available on Seer’s investor website.
Seer (Nasdaq: SEER) confirmed receipt of two further revised, unsolicited, non-binding acquisition proposals for all outstanding shares of its Class A common stock. On July 28, 2026, the Radoff-JEC Group offered $2.55 per share in cash plus a contingent value right.
On July 29, 2026, Omid Farokhzad, M.D., Seer’s Chair and CEO, submitted a revised proposal for $2.45 per share in cash plus two separate contingent value rights. According to Seer, its previously constituted Special Committee, with advisors, will review both proposals and other alternatives. No stockholder action is required at this time.
Seer (Nasdaq: SEER) reported that, based on preliminary results from its 2026 Annual Meeting of Stockholders, stockholders voted to re-elect all seven director nominees to the Board. The company said it remains focused on executing its strategy, including expanding platform utilization and commercialization with cost discipline. Final voting results will be certified by an independent inspector and filed on Form 8-K with the SEC.
Summary not available.